Peptides vs SARMs
Peptides and SARMs (Selective Androgen Receptor Modulators) are both discussed in performance and wellness communities, but they work through entirely different mechanisms. SARMs are essentially more targeted steroids — they activate androgen receptors selectively — while peptides are signaling molecules that work through non-androgenic pathways.
| Category | ||
|---|---|---|
| What They Are | Amino acid chains that signal biological processes (GH release, tissue repair, etc.) | Small molecules that selectively activate androgen receptors in muscle and bone |
| Mechanism | Diverse — GH secretion, tissue repair, appetite regulation, neuroprotection | Androgenic — selective activation of androgen receptors (like targeted steroids) |
| Testosterone Suppression | No (for most peptides) | Yes — SARMs suppress natural testosterone, though less than steroids |
| FDA Approval Status | Several are FDA-approved (semaglutide, PT-141, tesamorelin, etc.) | None are FDA-approved for any human use |
| WADA/Sports Ban | Some are banned (GH secretagogues); many are not | All SARMs are banned by WADA |
| Liver Toxicity | Minimal for most peptides | Significant — hepatotoxicity is a documented concern with oral SARMs |
| Primary Use Cases | Recovery, sleep, cognition, gut health, weight loss, skin, longevity | Muscle building, bone density, body recomposition |
| Safety Data | Varies — FDA-approved peptides have extensive data; others have less | Very limited — no completed Phase III trials for any SARM |
| Quality Control | Available through licensed compounding pharmacies | Mostly sold as research chemicals; quality highly variable |
| Post-Cycle Therapy | Not required | Often recommended due to testosterone suppression |
Summary
SARMs occupy a middle ground between peptides and steroids — they're more targeted than traditional steroids but still fundamentally androgenic. The key risk with SARMs is that despite being marketed as safer alternatives to steroids, they still suppress natural testosterone, carry liver toxicity risks, and have essentially no long-term human safety data. No SARM has completed Phase III clinical trials or received FDA approval. Peptides, by contrast, include multiple FDA-approved compounds with years of post-marketing safety data. The two classes serve different purposes: SARMs are primarily for muscle building (the same goal as steroids, with somewhat fewer side effects), while peptides address a much broader range of health goals. For most people, peptides offer a better risk-benefit ratio and a legal, clinician-supervised pathway.